Bioxytran to Appear on ClearThink IR’s Virtual Live Event
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
- Wednesday, February 15th, 2023 12:00 EST
-星期三 二月十五日, 2023 12:00 東
- Virtual Fireside Chat via Paltalk Platform
-通過 Paltalk 平台進行虛擬爐邊聊天
BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that Bioxtran CCO Michael Sheikh will appear on ClearThink IR Virtual Live on Wednesday, February 15, 2023 at 12 noon ET.
波士頓，麻薩諸塞州，2023 年 2 月 14 日（環球美通社）-生物科技股份有限公司（OTCQB：BIXT）（「公司」），一家開發口服和靜脈藥物治療 COVID-19 和其他病毒引起的疾病的臨床階段生物技術公司宣布，Bioxtran CCO 邁克爾·謝赫將在 2023 年 2 月 15 日星期三中午 12 時正午出現在 ClearThink IR 虛擬直播中。
Event: ClearThink IR's Fireside Chat via Paltalk Platform (Interactive video, voice, and chat)
活動: 通過 Paltalk 平台 ClearThink IR 的爐邊聊天（交互式視頻，語音和聊天）
Date: February 15, 2023
日期：二零二三年二月十五日
Registration:
註冊:
Please click the registration link above to sign up and install Paltalk to register for the ClearThink Capital IR room. We suggest downloading the application prior to Wednesday's Noon event.
請單擊上面的註冊鏈接以註冊並安裝 Paltalk 以註冊 ClearThink 資本 IR 房間。我們建議您在星期三的中午活動之前下載該應用程序。
Step 1 – Click the link to download and install the Paltalk app
Step 2 – After creating an account on Paltalk, you'll be brought to "ClearThink Capital"
Step 3 – Follow the room and join us
步驟 1 — 單擊鏈接以下載並安裝 Paltalk 應用程序
步驟 2 — 在 Paltalk 上創建帳戶後，您將被帶到「明智資本」
步驟 3 — 關注會議室並加入我們
Time: 12:00 pm EST
時間: 美國東部標準時間
The ClearThink IR Virtual Live, powered by Paltalk, will be hosting a different CEO every Wednesday at 12 noon ET for a "fireside chat" followed by an engaging Q&A discussion offering a great opportunity for potential investors to learn about a company's product or service offerings and strategic initiatives of an emerging growth micro-cap company.
由 Paltalk 提供支持的 ClearThink IR 虛擬直播將在每週三中午 12 點舉辦不同的首席執行官進行「爐邊聊天」，然後進行引人入勝的問答討論，為潛在投資者提供了一個很好的機會，了解公司的產品或服務產品以及新興成長微型股公司的戰略舉措。
About Bioxytran, Inc.
關於 生物氧糖，公司。
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at
Bioxytran, Inc. 是一家臨床階段生物技術公司，致力於治療病毒學、退行性疾病和缺氧等重要醫療需求的新型療法。領先候選藥物 Prolectin-M 是一種新型的抗病毒藥物，旨在對抗炎症，纖維性和惡性疾病中涉及的膽固酮。Bioxytran 的其他發展計劃用於肺纖維化和中風治療。更多信息可在以下位置找到
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
投資者關係
邁克爾謝赫
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
前瞻性陳述
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
本新聞稿包括聯邦法律所定義的前瞻性聲明，包括與本新聞稿中描述的技術性能相關的聲明。這些前瞻性陳述通常以「相信」，「期望」，「預期」，「估計」，「意圖」，「計劃」和類似的表達式來標識，儘管並非所有前瞻性語句都包含這些識別詞語。此等陳述須承受重大風險、假設及不明朗因素。可能導致 Bioxytran 實際結果與前瞻性陳述所擬定的結果有很大差異的已知重大因素，請參閱公司截至 2021 年 12 月 31 日止財政年度的 10-K 表年報中的前瞻性聲明和風險因素，以及其他向證券交易委員會提交的其他風險因素。Bioxytran 沒有義務糾正或更新任何前瞻性聲明，無論是由於新信息，未來事件或其他結果，除非在聯邦證券法規定的範圍內。
譯文內容由第三人軟體翻譯。